Nihon Medi-physics Company, Limited

Sumitomo Chemical Company, Limited

Keietsu Takahashi

Nobuo Ueda

Masaaki Hazue

Akira Yokoyama

Kazuhiro Kimura

Hirohiko Yamauchi

Yoshifumi Shirakami

Miki Kurami

Akira Yoshitake

Kunio Shiba

Yoshiro Ohmomo

Makoto Fukushima

Kenichi Morishita

Miki Hayashi

Yoshiaki Murakami

There is disclosed an agent for preventing the adhesion of thallium 201 to a container which comprises a reducing substance as an active ingredient. There is also disclosed a radioactive diagnostic agent wherein the adhesion of thallium 201 to a container is prevented which comprises thallium 201 and a reducing substance.

Method for preventing adhesion of thallium 201 to container

A radioactive diagnostic agent which comprises (1) the unit of a polyformyl compound having at least three formyl groups per molecule, (2) at least two units of an amino group-containing chelating compound bonded to the polyformyl compound with intervention of a methyleneimine linkage (--CH.dbd.N--) or a methyleneamine linkage (--CH.sub.2 NH--) formed by the condensation between the formyl group in the polyformyl compound and the amino group in the chelating compound, optionally followed by reduction, (3) at least one unit of an amino group-containing physiologically active substance bonded to the polyformyl compound with intervention of a methyleneimine linkage or a methyleneamine linkage formed by the condensation between the formyl group in the polyformyl compound and the amino group in the physiologically active substance, optionally followed by reduction, and (4) at least two radioactive metallic elements of which each is bonded to the chelating compound through a chelating bond.

Chemical product usable as a non-radioactive carrier

The present invention relates to a chemical product usable as a non-radioactive carrier which comprises (1) a unit of a polyformyl compound having at least three formyl groups per molecule, (2) at least two units of an amino group-containing chelating compound bonded to the polyformyl compound by a methyleneimine linkage (--CH.dbd.N--) or a methyleneamine linkage (--CH.sub.2 NH--) between a formyl group in the polyformy compound and an amino group in the chelating compound, optionally followed by reduction, (3) at least one unit of an amino group-containing physiologically active substance bonded to the polyformyl compound by a methyleneimine linkage or a methyleneamine linkage between a formyl group in the polyformyl compound and the amino group in the physiologically active substance, optionally followed by reduction.

A radioactive diagnostic or therapeutic agent, which comprises a metallic element-labeled high molecular compound which comprises one unit of (1) a polyamine compound having at least three amino groups in the side chains per molecule, at least two units of (2) a chelate-forming compound having a carboxyl group, at least one unit of (3) a physiologically active substance and (4) at least two radioactive metallic elements, each unit of the chelate-forming compound (2) and the physiologically active substance (3) being combined to any of the amino groups in the side chains of the polyamine compound (1) and each of the radioactive metallic element (4) being chelate-bonded to the chelate-forming compound (2).

High molecular compounds having amino groups, and their utilization

A radioactive diagnostic agent which comprises (1) a unit of a polyformyl compound having at least three formyl groups per molecule, (2) at least two units of an amino group-containing chelating compound bonded to the polyformyl compound a methyleneimine linkage (--CH.dbd.N--) or a methyleneamine linkage (--.sub.2 NH--) formed by the condensation between the formyl group in the polyformyl compound and the amino group in the chelating compound, optionally followed by reduction, (3) at least one unit of an amino group-containing physiologically active substance bonded to the polyformyl compound by a methyleneimine linkage or a methyleneamine linkage formed by the condensation between the formyl group in the polyformyl compound and the amino group in the physiologically active substance, optionally followed by reduction, and (4) at least two radioactive metallic elements of which each is bonded to the chelating compound through a chelating bond.

Radioactive diagnostic agent

A radioactive diagnostic agent having high labeling efficiency, prepared by bringing an aqueous solution of a radioactive metallic element contaminated with a non-radioactive metallic ions into contact with a non-radioactive carrier comprising a carrier substance having a chelate-forming property and optionally a physiologically active substance chemically bonded thereto, at least one of said aqueous solution and said non-radioactive carrier comprising at least one reductive material chosen from ascorbic acid and erythrobic acid, and their salts and esters.

Increasing labeling efficiency by forming diagnostic agent in the

A protein-polysuccinimide complex wherein a biologically active protein is combined with a polysuccinimide having a mean molecular weight of 2,000 to 1,000,000 and consisting of constitutive units represented by the following formulae: ##STR1## Said complex can be labelled with a radio-metal and can be used as a radioactive diagnostic in the field of nuclear medicine.

Complex of biologically active protein with reactive high polymer having

A radioactive diagnostic agent for bone scanning, which comprises .sup.99m Tc and a non-radioactive carrier comprising (A) at least one chosen from methanehydroxydiphosphonic acid and their salts and (B) at least one reducing agent for pertechnetates in a weight ratio of about 1:1 to 7:1 and prevents the accumulation of radioactivity in liver so that definite diagnosis can be assured.

Growing community of inventors

Itami, Japan

Keietsu Takahashi